Are metabolites of l-deprenyl (selegiline) useful or harmful? Indications from preclinical research

S. Yasar, J. P. Goldberg, S. R. Goldberg

Research output: Contribution to journalReview articlepeer-review

34 Scopus citations


A frequent topic of controversy has been whether metabolism of l-deprenyl (selegiline) to active metabolites is a detriment to clinical use. This paper reviews possible roles of the metabolites of l-deprenyl in producing unwanted adverse side effects or in augmenting or mediating its clinically useful actions. Levels of l-amphetamine and l-methamphetamine likely to be reached, even with excessive intake of l-deprenyl, would be unlikely to produce neurotoxicity and there is no preclinical or clinical evidence of abuse liability of l-deprenyl. In contrast, there is evidence that l-amphetamine and l-methamphetamine have some qualitatively different actions than their disomer counterparts on EEG and cognitive functioning which might result in beneficial clinical effects and complement beneficial clinical actions of l-deprenyl itself.

Original languageEnglish (US)
Pages (from-to)61-73
Number of pages13
JournalJournal of Neural Transmission, Supplement
Issue number48
StatePublished - 1996

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health
  • Biological Psychiatry


Dive into the research topics of 'Are metabolites of l-deprenyl (selegiline) useful or harmful? Indications from preclinical research'. Together they form a unique fingerprint.

Cite this